The study's primary goal is to assess the therapy’s tolerability, pharmacokinetics and safety in healthy volunteers.
In recent trading, Palisade Bio Inc (PALI) stock price has shown some volatility, fluctuating -17.41% over the last five trades and -6.
Company on track to report topline data in first half of 2025Positive preliminary data from all five single ascending dose (SAD) cohorts ranging ...
Bio announced the completion of all five planned Single Ascending Dose, SAD, cohorts and the commencement of the Multiple Ascending Dose ...
CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company with a market capitalization of ...
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on ...
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and ...
(MENAFN- GlobeNewsWire - Nasdaq) Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”,“Palisade Bio”, or the ...
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback